Akero (AKRO) CDO exercises 3,527 and 4,739 stock options, filing

Akero Therapeutics (AKRO) disclosed an insider transaction by its Chief Development Officer.

Rhea-AI Filing Summary

Akero Therapeutics (AKRO) disclosed an insider transaction by its Chief Development Officer. On 11/04/2025, the officer exercised stock options and acquired 3,527 shares at $28.35 and 4,739 shares at $21.10 (code M). Following these transactions, the officer reported ownership of 74,800 shares, held directly.

A footnote states the reported amount was adjusted to correct a prior overstatement of common stock ownership. Another footnote confirms the options were vested and currently exercisable.

Insider Trade Summary

8,266 shares exercised/converted

Exercise 4 txns

Insider Yale Catriona

Role Chief Development Officer

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	3,527	$0.00	$0.00
Exercise	Stock Option (Right to Buy)	4,739	$0.00	$0.00
Exercise	Common Stock	3,527	$28.35	$100K
Exercise	Common Stock	4,739	$21.10	$100K

Holdings After Transaction: Stock Option (Right to Buy) — 0 contracts (Direct); Common Stock — 74,800 shares (Direct)

Footnotes (2)

1. F1. The reported amount has been adjusted to correct for an overstatement in the Reporting Person's previously reported common stock ownership.
2. F2. The options are vested and currently exercisable.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Akero (AKRO) report in this Form 4?

The Chief Development Officer exercised options and acquired 3,527 shares at $28.35 and 4,739 shares at $21.10 on 11/04/2025.

How many Akero (AKRO) shares does the insider own after the transactions?

The officer reported 74,800 shares beneficially owned directly after the transactions.

Were the Akero (AKRO) options exercisable at the time of the transaction?

Yes. A footnote states the options were vested and currently exercisable.

What do the transaction codes mean in Akero (AKRO)’s Form 4?

Code M indicates an option exercise that resulted in acquiring common stock.

Did Akero (AKRO) note any corrections to prior ownership reports?

Yes. A footnote says the reported amount was adjusted to correct a prior overstatement of common stock ownership.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/06/2025 - 07:00 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Yale Catriona

(Last) (First) (Middle)

601 GATEWAY BOULEVARD

SUITE 350

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Akero Therapeutics, Inc. [ AKRO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Development Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/04/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/04/2025		M		3,527	A	$28.35	70,061	D
Common Stock	11/04/2025		M		4,739	A	$21.1	74,800(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$28.35	11/04/2025		M			3,527	(2)	12/07/2030	Common Stock	3,527	$0	0	D
Stock Option (Right to Buy)	$21.1	11/04/2025		M			4,739	(2)	12/07/2031	Common Stock	4,739	$0	0	D

Explanation of Responses:

1. The reported amount has been adjusted to correct for an overstatement in the Reporting Person's previously reported common stock ownership.

2. The options are vested and currently exercisable.

	/s/ Jonathan Young, Attorney-in-Fact	11/06/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.